SCHEMBL8206445

SCHEMBL8206445

O=C(Nc1sc2c(c1C(=O)Nc1ccccc1)CCCC2)c1ccccc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.80
MAPT P10636 3/20 0.80
THRB P10828 2/20 0.80
RAB9A P51151 4/20 0.77
NPC1 O15118 3/20 0.77
KMT2A Q03164 3/20 0.77
MEN1 O00255 2/20 0.77
ALDH1A1 P00352 1/20 0.77
FLT3 P36888 1/20 0.75
LMNA P02545 1/20 0.74
POLB P06746 1/20 0.74
HPGD P15428 1/20 0.74
SMN1; SMN2 Q16637 1/20 0.74
ESR2 Q92731 1/20 0.74
CTDSP1 Q9GZU7 1/20 0.74
TDP1 Q9NUW8 1/20 0.74
ANO1 Q5XXA6 5/20 0.72
CASP3 P42574 1/20 0.71
SENP7 Q9BQF6 1/20 0.71
ANO2 Q9NQ90 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20704645 0.88 MAPT (0.70) TP53MAPTTHRBRAB9ANPC1
SCHEMBL20704808 0.88 MAPT (0.68) TP53MAPTTHRBRAB9ANPC1
SCHEMBL3916274 0.88 KMT2A (0.97) TP53MAPTRAB9ANPC1KMT2A
SCHEMBL919352 0.87 MEN1 (1.00) TP53MAPTRAB9ANPC1KMT2A
SCHEMBL20340283 0.86 MAPT (0.96) TP53MAPTTHRBRAB9ANPC1
SCHEMBL21853924 0.86 ANO1 (0.77) TP53MAPTTHRBKMT2AMEN1
SCHEMBL22435132 0.86 TP53 (0.68) TP53MAPTTHRBRAB9ANPC1
SCHEMBL20710947 0.86 ANO1 (0.72) TP53MAPTTHRBKMT2AMEN1
SCHEMBL3128198 0.86 FLT3 (1.00) MAPTRAB9ANPC1KMT2AMEN1
SCHEMBL21247366 0.85 RAB9A (1.00) TP53MAPTRAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6143777-A ENZYME INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-11-07 US claimed
US-20230113225-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL THERAPEUTICS, INC. (US) 2023-04-13 US disclosed
US-20230103887-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL THERAPEUTICS, INC. (US) 2023-04-06 US disclosed
US-11505528-B2 Inhibitors of microbially induced amyloid AXIAL THERAPEUTICS, INC. (US) 2022-11-22 US disclosed
US-11505528-B2 Inhibitors of microbially induced amyloid AXIAL THERAPEUTICS, INC. (US) 2022-11-22 US disclosed
WO-2022098879-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-12 WO disclosed
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-05 US disclosed
US-20210052503-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2021-02-25 US disclosed
WO-2020227437-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL BIOTHERAPEUTICS, INC. (US) 2020-11-12 WO disclosed
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2020-09-17 US disclosed
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2020-09-17 US disclosed
EP-3664822-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID Axial Biotherapeutics, Inc. (US) 2020-06-17 EP disclosed
WO-2019028456-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2019-02-07 WO disclosed
WO-2019028456-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2019-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103887-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP TP53 2454/4885MAPT 7/4885THRB 4068/4885
US-11505528-B2 Inhibitors of microbially induced amyloid SNCA, PARK7, PRNP TP53 2454/4885MAPT 7/4885THRB 4068/4885
US-20230113225-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP TP53 2666/4885MAPT 9/4885THRB 4073/4885
US-20210052503-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME APC, SNCA, PARK7 TP53 1765/4885MAPT 24/4885THRB 4729/4885
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME APC, SNCA, PARK7 TP53 1765/4885MAPT 24/4885THRB 4729/4885
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP TP53 2454/4885MAPT 7/4885THRB 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.